An orally available inhibitor of native Bcr-Abl tyrosine kinase (IC50 = 0.37 nM) as well as various clinically important mutant forms including Bcr-AblT315I (IC50 = 2 nM); inhibits tumor growth in a Ba/F3 Bcr- AblT315I xenograft model of chronic myeloid leukemia in mice upon oral dosing at 10-30 mg/kg